AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31273505 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group receiving the same CRC education handbook only at discharge preparation
Number of subjects: 68
Study 29357331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy with 8 pulses per second (medium‐dose)
Number of subjects: 231
Study 29357331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy with one pulse per second (low‐dose)
Number of subjects: 231
Study 29357331 — intervention group
Group type: COMPARATOR
Intervention: Continuous mode fluoroscopy (high‐dose)
Number of subjects: 231
Study 29357331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy (both medium and low doses)
Number of subjects: 231
Study 27225977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic NMES
Number of subjects: 122
Study 27225977 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-triggered NMES
Number of subjects: 122
Study 27225977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory stimulation
Number of subjects: 122
Study 25135244 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/mL gentamicin solution (four intratympanic injections, administered weekly)
Number of subjects: 3
Study 25135244 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of gentamicin solution and two injections of placebo (in random order)
Number of subjects: 3
Study 25135244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four injections)
Number of subjects: 3
Study 23052572 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral support for smoking cessation
Number of subjects: 452
Study 20160654 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 0.05 mg/kg per day
Number of subjects: 93
Study 20160654 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 0.2 mg/kg per day
Number of subjects: 93
Study 20160654 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 0.4 mg/kg per day
Number of subjects: 93
Study 20160654 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 93
Study 20160654 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil in participants with proteinuric renal disease
Number of subjects: 93
Study 19027898 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-7
Number of subjects: 120
Study 19027898 — intervention group
Group type: COMPARATOR
Intervention: PRP
Number of subjects: 120
Study 16877729 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel
Number of subjects: 56
Study 16877729 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel every 3 weeks
Number of subjects: 56
Study 14610417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate
Number of subjects: 0
Study 14610417 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 0
Study 10781769 — intervention group
Group type: EXPERIMENTAL
Intervention: Crosswire guidewire strategy
Number of subjects: 0
Study 10781769 — intervention group
Group type: COMPARATOR
Intervention: Conventional guidewire strategy
Number of subjects: 0
Study 9119091 — intervention group
Group type: EXPERIMENTAL
Intervention: Early induction of labour with oxytocin at a rate of 2.5 mU/min
Number of subjects: 154
Study 9119091 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 154
Study 9119091 — intervention group
Group type: EXPERIMENTAL
Intervention: Early induction of labour with oxytocin
Number of subjects: 154
Study 1729430 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Technique (RT)
Number of subjects: 40
Study 1729430 — intervention group
Group type: COMPARATOR
Intervention: Control (no RT)
Number of subjects: 40
Study 6729454 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 6729454 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0
Study 6729454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30807405 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorelle Y mesh
Number of subjects: 62
Study 30807405 — intervention group
Group type: COMPARATOR
Intervention: Flat mesh
Number of subjects: 62
Study 29620692 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50 mg/d
Number of subjects: 264
Study 29620692 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20-40 mg/d
Number of subjects: 264
Study 26408647 — intervention group
Group type: EXPERIMENTAL
Intervention: Working while seated
Number of subjects: 45
Study 26408647 — intervention group
Group type: EXPERIMENTAL
Intervention: Working while standing
Number of subjects: 45
Study 26408647 — intervention group
Group type: EXPERIMENTAL
Intervention: Working while walking at low intensity
Number of subjects: 45
Study 24562504 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum IPV (emerged and repeated)
Number of subjects: 734
Study 24562504 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissipated postpartum IPV
Number of subjects: 734
Study 24562504 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum IPV prevalence
Number of subjects: 734
Study 23018351 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 11
Study 23018351 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 11
Study 20496820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral injection of 20 units of botulinum toxin into each side of the internal anal sphincter
Number of subjects: 40
Study 20496820 — intervention group
Group type: COMPARATOR
Intervention: Posterior injection of 25 units of botulinum toxin into the midline posteriorly
Number of subjects: 40
Study 17279491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh repair
Number of subjects: 300
Study 17279491 — intervention group
Group type: COMPARATOR
Intervention: Non-mesh repair
Number of subjects: 300
Study 16218514 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline (0.1%)
Number of subjects: 20
Study 16218514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (120 mg)
Number of subjects: 20
Study 16218514 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 20
Study 16218514 — intervention group
Group type: COMPARATOR
Intervention: Neither sympathicomimetic
Number of subjects: 20
Study 12003052 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic SF-36
Number of subjects: 115
Study 12003052 — intervention group
Group type: COMPARATOR
Intervention: Paper SF-36
Number of subjects: 115
Study 10436448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) therapy, 40 mg enoxaparin every 12 hours for 7 days, then 40 mg once daily for 3 months
Number of subjects: 165
Study 10436448 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant therapy (coumarin), standard unfractionated heparin followed by coumarin for 3 months
Number of subjects: 165
Study 10436448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) therapy
Number of subjects: 165
Study 10436448 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant therapy (coumarin)
Number of subjects: 165
Study 8786960 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg tablets
Number of subjects: 16
Study 8786960 — intervention group
Group type: COMPARATOR
Intervention: 400-mg suspension
Number of subjects: 16
Study 2081489 — intervention group
Group type: EXPERIMENTAL
Intervention: nabumetone 1 g at night
Number of subjects: 243
Study 2081489 — intervention group
Group type: COMPARATOR
Intervention: slow release diclofenac 100 mg at night
Number of subjects: 243
Study 656778 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction by diet or jejunoileal shunt
Number of subjects: 70
Study 656778 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal shunt
Number of subjects: 70
Study 656778 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 70
Study 31907645 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1101 (3 mg/kg, intravenously)
Number of subjects: 82
Study 31907645 — intervention group
Group type: COMPARATOR
Intervention: Avastin® (3 mg/kg, intravenously)
Number of subjects: 82
Study 31907645 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1101
Number of subjects: 82
Study 31907645 — intervention group
Group type: COMPARATOR
Intervention: Avastin®
Number of subjects: 82
Study 31907645 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1101 and Avastin®
Number of subjects: 82
Study 30638903 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-management program
Number of subjects: 49
Study 28099439 — intervention group
Group type: EXPERIMENTAL
Intervention: Single NSE measurement at 48 hours
Number of subjects: 685
Study 28099439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three NSE measurements
Number of subjects: 685
Study 28099439 — intervention group
Group type: EXPERIMENTAL
Intervention: Easily applicable combinations of serial NSE measurements
Number of subjects: 685
Study 25869385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, cyclophosphamide, vincristine, and prednisone (BCCA cohort)
Number of subjects: 581
Study 25869385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (PRIMA trial)
Number of subjects: 581
Study 25869385 — intervention group
Group type: COMPARATOR
Intervention: Rituximab maintenance (PRIMA trial)
Number of subjects: 581
Study 25869385 — intervention group
Group type: COMPARATOR
Intervention: Observation (PRIMA trial)
Number of subjects: 581
Study 23110683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Number of subjects: 35
Study 23110683 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol
Number of subjects: 35
Study 21884871 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.0 mg twice daily for the first day, followed by 0.5 mg twice daily for patients ≥70 kg; halved doses for patients <70 kg)
Number of subjects: 360
Study 21884871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 19078934 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling (ST)
Number of subjects: 78
Study 19078934 — intervention group
Group type: COMPARATOR
Intervention: Risk Tool (RT)
Number of subjects: 78
Study 16919479 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 18
Study 16919479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16137049 — intervention group
Group type: EXPERIMENTAL
Intervention: UTI 5000 U/kg
Number of subjects: 30
Study 16137049 — intervention group
Group type: COMPARATOR
Intervention: NS 100 ml (Control)
Number of subjects: 30
Study 11079282 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 10 mg twice/day for a maximum of 28 days
Number of subjects: 62
Study 11079282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 10178676 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 50
Study 10178676 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Processing (PP)
Number of subjects: 50
Study 10178676 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropheresis
Number of subjects: 50
Study 7871058 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg)
Number of subjects: 12
Study 7871058 — intervention group
Group type: EXPERIMENTAL
Intervention: ritanserin (5 mg)
Number of subjects: 12
Study 7871058 — intervention group
Group type: EXPERIMENTAL
Intervention: ritanserin (5 mg) + d-fenfluramine (30 mg)
Number of subjects: 12
Study 3527626 — intervention group
Group type: EXPERIMENTAL
Intervention: Careful dietary adherence and weight reduction
Number of subjects: 107
Study 3527626 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor dietary adherence and persistent obesity
Number of subjects: 107
Study 3527626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet therapy
Number of subjects: 107
Study 3527626 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin responses
Number of subjects: 107
Study 30875481 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance-low-aerobic exercise (Re)
Number of subjects: 100
Study 30875481 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-resistance-high-aerobic exercise (rE)
Number of subjects: 100
Study 30875481 — intervention group
Group type: COMPARATOR
Intervention: Low-resistance-low-aerobic exercise (re)
Number of subjects: 100
Study 29085969 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding and multivitamin supplementation (vitamins A, C, D)
Number of subjects: 120
Study 29085969 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of urinary tract stones
Number of subjects: 120
Study 29085969 — intervention group
Group type: COMPARATOR
Intervention: ApaI and FokI VDR gene polymorphisms
Number of subjects: 120
Study 29085969 — intervention group
Group type: EXPERIMENTAL
Intervention: CA genotype of ApaI polymorphism
Number of subjects: 120
Study 29085969 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele of ApaI polymorphism
Number of subjects: 120
Study 29085969 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercalciuria
Number of subjects: 120
Study 26792776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle electrolysis (PNE) on the patellar tendon
Number of subjects: 22
Study 26792776 — intervention group
Group type: COMPARATOR
Intervention: Control group (HRV recorded for 10 min at rest and during exhaustive US examination)
Number of subjects: 22
Study 24673716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine with short-term intensified EC-MPS dosing (2160 mg/day to week 6, 1440 mg/day thereafter) and corticosteroids
Number of subjects: 180
Study 24673716 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cyclosporine with standard EC-MPS dosing (1440 mg/day) and corticosteroids
Number of subjects: 180
Study 24673716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine with short-term intensified EC-MPS dosing
Number of subjects: 180
Study 24673716 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cyclosporine with standard EC-MPS dosing
Number of subjects: 180
Study 22469884 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (50 mg/day i.v.)
Number of subjects: 287
Study 22469884 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (5 mg/kg/day p.o.)
Number of subjects: 287
Study 21336020 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL) using video
Number of subjects: 44
Study 21336020 — intervention group
Group type: COMPARATOR
Intervention: Traditional live lecture
Number of subjects: 44
Study 18614570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib sodium (0.3, 1, and 3 mg)
Number of subjects: 0
Study 18614570 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 0
Study 16086613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg
Number of subjects: 12
Study 16086613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11808825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg oral dose
Number of subjects: 0
Study 11808825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 2.5 to 10 mg tid
Number of subjects: 0
Study 11808825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine multiple dosing
Number of subjects: 0
Study 11808825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg tid in elderly subjects
Number of subjects: 0
Study 11808825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine in subjects with mild hepatic insufficiency
Number of subjects: 0
Study 11808825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine in males and females
Number of subjects: 0
Study 11808825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine dosing recommendations
Number of subjects: 0
Study 10428307 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavonoid supplement (55 mg daily)
Number of subjects: 59
Study 7767419 — intervention group
Group type: EXPERIMENTAL
Intervention: General ultrasound screening
Number of subjects: 11925
Study 7767419 — intervention group
Group type: COMPARATOR
Intervention: Selective ultrasound screening
Number of subjects: 11925
Study 7767419 — intervention group
Group type: COMPARATOR
Intervention: No ultrasound screening
Number of subjects: 11925
Study 2258157 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (twice daily at a dose reducing heart rate by 25%)
Number of subjects: 126
Study 2258157 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (intravariceal and extravariceal injections of Polidocanol)
Number of subjects: 126
Study 2258157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin K orally)
Number of subjects: 126
Study 2258157 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol vs. Placebo
Number of subjects: 126
Study 2258157 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol vs. Sclerotherapy
Number of subjects: 126
Study 2258157 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy vs. Placebo
Number of subjects: 126
Study 7026693 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Escherichia coli endotoxin (0.1-0.5 ng/kg)
Number of subjects: 0
Study 7026693 — intervention group
Group type: EXPERIMENTAL
Intervention: Phthalylated reference endotoxin (up to 1,000 ng/kg)
Number of subjects: 0
Study 31775407 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgrade technique for DRG stimulation
Number of subjects: 39
Study 28410865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3mg/kg intravenously every 2 weeks (TBP)
Number of subjects: 406
Study 28410865 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab 3mg/kg intravenously every 2 weeks (NTBP)
Number of subjects: 406
Study 28410865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (TBP)
Number of subjects: 406
Study 25886635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokishigyakukagoshuyushokyoto (TJ‐38)
Number of subjects: 58
Study 25886635 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 23746562 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine and caffeine (400 mg/d PS and 100 mg/d caffeine) for 2 weeks
Number of subjects: 0
Study 23746562 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study 21283958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond™
Number of subjects: 49
Study 21283958 — intervention group
Group type: COMPARATOR
Intervention: Steri-Strip™
Number of subjects: 49
Study 19341846 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mcg ethinyl estradiol (EE) daily during the hormone-free interval
Number of subjects: 0
Study 19341846 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the hormone-free interval
Number of subjects: 0
Study 17445751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice a day
Number of subjects: 38
Study 15117727 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 28
Study 15117727 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 28
Study 11341473 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Dysport® 500 to 1500U or Botox® 100 to 300U)
Number of subjects: 0
Study 11341473 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity or electrical stimulation of the injected muscles
Number of subjects: 0
Study 11341473 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial casting
Number of subjects: 0
Study 9118978 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (N; 1.2 mg; 3 ml)
Number of subjects: 8
Study 9118978 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P; 0.9% NaCl saline; 3 ml)
Number of subjects: 8
Study 8158817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Number of subjects: 40119
Study 8158817 — intervention group
Group type: COMPARATOR
Intervention: Control (Hepatitis B vaccine)
Number of subjects: 40119
Study 3341259 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut meals (walnuts, almonds, peanuts, hazelnuts)
Number of subjects: 137
Study 3341259 — intervention group
Group type: COMPARATOR
Intervention: Bread meals
Number of subjects: 137
Study 3341259 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut
Number of subjects: 137
Study 3341259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (50 mg) with Brazil nuts and peanuts
Number of subjects: 137
Study 30157771 — intervention group
Group type: EXPERIMENTAL
Intervention: auditive distraction
Number of subjects: 206
Study 30157771 — intervention group
Group type: EXPERIMENTAL
Intervention: visual distraction
Number of subjects: 206
Study 30157771 — intervention group
Group type: EXPERIMENTAL
Intervention: combination distraction
Number of subjects: 206
Study 30157771 — intervention group
Group type: COMPARATOR
Intervention: control group (no distraction)
Number of subjects: 206
Study 26796612 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine-atropine combination (Group N, n = 45)
Number of subjects: 90
Study 26796612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (Group S, n = 45)
Number of subjects: 90
Study 26796612 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 90
Study 25577909 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive traditional Chinese medicine therapy including passive exercise training (0-2 weeks), transition to active exercise training (3-4 weeks), and active exercise training (5-12 weeks)
Number of subjects: 32
Study 25577909 — intervention group
Group type: COMPARATOR
Intervention: Control group received past procedure therapy
Number of subjects: 32
Study 23109689 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 239
Study 23109689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus carboplatin
Number of subjects: 239
Study 23109689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus carboplatin in patients with squamous tumors
Number of subjects: 239
Study 20609640 — intervention group
Group type: EXPERIMENTAL
Intervention: JAPAN arm (EES implantation)
Number of subjects: 183